tiprankstipranks
Advertisement
Advertisement

NGNE Stock Latest News

Neurogene: Buy Rating Reiterated as NGN-401 Rett Program Advances Toward BLA with $70 Price Target Unchanged
RatingsNeurogene: Buy Rating Reiterated as NGN-401 Rett Program Advances Toward BLA with $70 Price Target Unchanged
3d ago
NGNE
Neurogene: EMBOLDEN Trial Milestone, Competitive Lead Support Reiterated Buy and Unchanged $60 Price Target
PremiumRatings
Neurogene: EMBOLDEN Trial Milestone, Competitive Lead Support Reiterated Buy and Unchanged $60 Price Target
4d ago
NGNE
Neurogene Completes Dosing in Embolden Rett Trial
PremiumCompany Announcements
Neurogene Completes Dosing in Embolden Rett Trial
4d ago
8K
NGNE
Neurogene completes dosing in Embolden trial of NGN-401
PremiumThe Fly
Neurogene completes dosing in Embolden trial of NGN-401
4d ago
NGNE
Neurogene Stockholders Vote on Directors and Executive Pay
PremiumCompany Announcements
Neurogene Stockholders Vote on Directors and Executive Pay
7d ago
8K
NGNE
Neurogene initiated with a Buy at Rodman & Renshaw
PremiumThe FlyNeurogene initiated with a Buy at Rodman & Renshaw
9d ago
NGNE
Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway
Premium
Ratings
Analyst Reiterates Buy on Neurogene, Maintains $70 Price Target on Promising NGN-401 Profile and Solid Cash Runway
25d ago
NGNE
Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target
Premium
Ratings
Neurogene Maintains Buy Rating as Embolden Trial Progresses and Cash Runway Supports Unchanged $180 Price Target
30d ago
NGNE
Neurogene reports Q1 EPS ($1.39), consensus ($1.27)
PremiumThe Fly
Neurogene reports Q1 EPS ($1.39), consensus ($1.27)
1M ago
NGNE
Is NGNE a Buy, Before Earnings?
PremiumPre-Earnings
Is NGNE a Buy, Before Earnings?
1M ago
NGNE
Neurogene to present on ICV delivery in CNS-targeted gene therapy
PremiumThe Fly
Neurogene to present on ICV delivery in CNS-targeted gene therapy
1M ago
NGNE
Neurogene initiated with a Buy at Guggenheim
PremiumThe Fly
Neurogene initiated with a Buy at Guggenheim
1M ago
NGNE
Neurogene Expands Leadership Team to Drive NGN-401 Commercialization
PremiumCompany AnnouncementsNeurogene Expands Leadership Team to Drive NGN-401 Commercialization
2M ago
8K
NGNE
Neurogene appoints Christy Shafer as CCO
Premium
The Fly
Neurogene appoints Christy Shafer as CCO
2M ago
NGNE
Compelling Risk‑Reward in Neurogene’s NGN-401: Differentiated Gene Therapy Approach in Rett Syndrome Supports Buy Rating
Premium
Ratings
Compelling Risk‑Reward in Neurogene’s NGN-401: Differentiated Gene Therapy Approach in Rett Syndrome Supports Buy Rating
2M ago
NGNE
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
PremiumMarket News
3 Best High-Risk, High-Reward Stocks to Buy Now, According to Analysts – 4/9/2026
2M ago
UPB
AIOT
Neurogene price target lowered to $180 from $200 at Canaccord
PremiumThe Fly
Neurogene price target lowered to $180 from $200 at Canaccord
2M ago
NGNE
Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
PremiumRatings
Buy Rating Backed by Strong NGN-401 Clinical Progress, De-Risking Efficacy Data, and Solid Cash Runway in Rett Syndrome
3M ago
NGNE
Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts
PremiumRatings
Buy Rating Underpinned by De-Risked NGN‑401 Development, Aligned Manufacturing Strategy, and Cash Runway Through Key 2027–28 Catalysts
3M ago
NGNE
Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway
PremiumCompany AnnouncementsNeurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway
3M ago
NGNE
1 Top Stock to Buy Now with 350% Upside, 3/24/2026, According to Top Analysts
Premium
Market News
1 Top Stock to Buy Now with 350% Upside, 3/24/2026, According to Top Analysts
3M ago
NGNE
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
Premium
The Fly
Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat
3M ago
EL
RL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >